[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Decoy Therapeutics Inc (DCOY)

Decoy Therapeutics Inc (DCOY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,077
  • Shares Outstanding, K 590
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,520 K
  • EBIT $ -15 M
  • EBITDA $ -15 M
  • 60-Month Beta 0.64
  • Price/Sales 9.03
  • Price/Cash Flow N/A
  • Price/Book 0.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-21.73
  • Growth Rate Est. (year over year) +4,697.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.40 +7.94%
on 08/18/26
5.63 -34.81%
on 07/20/26
-1.94 (-34.58%)
since 07/17/26
3-Month
3.40 +7.94%
on 08/18/26
13.51 -72.83%
on 06/29/26
-0.98 (-21.08%)
since 05/18/26
52-Week
3.40 +7.94%
on 08/18/26
80.28 -95.43%
on 08/19/25
-76.49 (-95.42%)
since 08/18/25

Most Recent Stories

More News
Decoy Therapeutics: Q2 Earnings Snapshot

Decoy Therapeutics: Q2 Earnings Snapshot

DCOY : 3.67 (+4.26%)
Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform

Portfolio now spans seven patent families and 19 pending applications across seven jurisdictions, protecting antiviral peptide conjugates, the methods used to make them, their formulations, and the design...

DCOY : 3.67 (+4.26%)
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats

Lead D-MAV demonstrates cross-viral family fusion inhibition, validating the platform; opens a new program in filovirus pandemic preparedness

DCOY : 3.67 (+4.26%)
Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors

CAMBRIDGE, Mass. , July 15, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered...

DCOY : 3.67 (+4.26%)
Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing

HOUSTON , June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category...

DCOY : 3.67 (+4.26%)
Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London

Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development

DCOY : 3.67 (+4.26%)
Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors

CAMBRIDGE, Mass. , June 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered...

DCOY : 3.67 (+4.26%)
Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic

Collaboration supports Phase 1 and Phase 2a human proof-of-concept studies for new antiviral category designed to address multiple viruses with a single adaptable therapeutic

DCOY : 3.67 (+4.26%)
Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board

Appointment deepens scientific leadership as Decoy advances its Designable Multi-Antiviral pipeline toward clinical development

DCOY : 3.67 (+4.26%)
Decoy Therapeutics: Q1 Earnings Snapshot

Decoy Therapeutics: Q1 Earnings Snapshot

DCOY : 3.67 (+4.26%)

Business Summary

Decoy Therapeutics Inc. is a preclinical-stage biotechnology company which target serious unmet medical needs. The Company's initial pipeline is focused on respiratory viruses and GI cancers. Decoy Therapeutics Inc., formerly known as Salarius Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 4.10
2nd Resistance Point 3.90
1st Resistance Point 3.79
Last Price 3.67
1st Support Level 3.48
2nd Support Level 3.28
3rd Support Level 3.17

See More

52-Week High 80.28
Fibonacci 61.8% 50.91
Fibonacci 50% 41.84
Fibonacci 38.2% 32.77
Last Price 3.67
52-Week Low 3.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.